Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids

Benoit Stijlemans,Patrick De Baetselier,Inge Van Molle,Laurence Lecordier,Erika Hendrickx,Ema Romão,Cécile Vincke,Wendy Baetens,Steve Schoonooghe,Gholamreza Hassanzadeh-Ghassabeh,Hannelie Korf,Marie Wallays,Joar E. Pinto Torres,David Perez-Morga,Lea Brys,Oscar Campetella,María S. Leguizamón,Mathieu Claes,Sarah Hendrickx,Dorien Mabille,Guy Caljon,Han Remaut,Kim Roelants,Stefan Magez,Jo A. Van Ginderachter,Carl De Trez
DOI: https://doi.org/10.1038/s41467-024-46067-4
IF: 16.6
2024-02-27
Nature Communications
Abstract:Abstract Human African trypanosomiasis or sleeping sickness, caused by the protozoan parasite Trypanosoma brucei , is characterized by the manipulation of the host’s immune response to ensure parasite invasion and persistence. Uncovering key molecules that support parasite establishment is a prerequisite to interfere with this process. We identified Q586B2 as a T. brucei protein that induces IL-10 in myeloid cells, which promotes parasite infection invasiveness. Q586B2 is expressed during all T. brucei life stages and is conserved in all Trypanosomatidae. Deleting the Q586B2-encoding Tb927.6.4140 gene in T. brucei results in a decreased peak parasitemia and prolonged survival, without affecting parasite fitness in vitro, yet promoting short stumpy differentiation in vivo. Accordingly, neutralization of Q586B2 with newly generated nanobodies could hamper myeloid-derived IL-10 production and reduce parasitemia. In addition, immunization with Q586B2 delays mortality upon a challenge with various trypanosomes, including Trypanosoma cruzi . Collectively, we uncovered a conserved protein playing an important regulatory role in Trypanosomatid infection establishment.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to identify and study a protein Q586B2 that plays a crucial role in the early stage of Trypanosoma brucei infection. Specifically, the paper focuses on the following aspects: 1. **Identification of Q586B2**: Through bioinformatics analysis, the authors discovered a new T. brucei protein Q586B2, which has structural homology with the Q4D6Q6 protein in T. cruzi. 2. **Function of Q586B2**: It was found that Q586B2 is expressed in all life - cycle stages of T. brucei and is conserved in all Trypanosomatidae. After deleting the gene Tb927.6.4140 that encodes Q586B2, the peak parasitemia of the parasite was significantly reduced, and the survival time of the host was prolonged, but the in - vitro adaptability of the parasite was not affected. 3. **Immunomodulatory role of Q586B2**: Q586B2 can induce myeloid cells to produce IL - 10, thereby promoting the invasiveness of parasite infection. In addition, the lack of Q586B2 leads to an enhanced early - stage inflammatory response and promotes short stumpy differentiation. 4. **Secretory characteristics of Q586B2**: Research has confirmed that Q586B2 is a secreted protein that can be released into the host in the early stage of infection, further affecting the host's immune response. 5. **Potential application value**: By generating new nanobodies against Q586B2, the production of IL - 10 induced by it can be blocked, and parasitemia can be reduced, thus providing a new strategy for the treatment of African trypanosomiasis. Meanwhile, immunization with Q586B2 can delay death caused by various trypanosome infections. In summary, this paper aims to reveal the important role of Q586B2 in T. brucei infection and explore its potential as a therapeutic target.